Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Avanir Pharmaceuticals Inc. (NASDAQ: AVNR) shares surged 16.28 percent to close at $5.00 a share Wednesday. The stock traded between $4.22 and $5.08 on volume of 7.99 million shares traded. The company presented at the Cowen & Company 34th Annual Healthcare Conference on Tuesday, March 4th and is scheduled to present at the 26th Annual ROTH Conference on Tuesday, March 11th. Shares of Avanir Pharmaceuticals are up approximately 48.0 percent year-to-date.
Get more information on Avanir Pharmaceuticals and free access to the in-depth equity report at:
DARA Biosciences Inc. (NASDAQ: DARA) shares spiked 8.62 percent to close at $3.15 a share Wednesday. The stock traded between $3.15 and $3.55 on volume 2.96 million shares traded. The company has signed a Medicare Part D Prescription Drug Program Reimbursement Agreement with the WellCare Group, which provides formulary status for Soltamox. Shares of DARA Biosciences are up approximately 16.0 percent year-to-date.
Get more information on DARA Biosciences and free access to the in-depth equity report at:
Peregrine Pharmaceuticals (NASDAQ: PPHM) shares soared 47.64 percent to close at $2.82 a share Wednesday. The stock traded between $1.98 and $2.88 on volume of 36.53 million shares traded. The company announced that its PS-targeting immunotherapy will be highlighted in three presentations at the Keystone Symposia conferences. Shares of Peregrine Pharmaceuticals are up approximately 100.0 percent year-to-date.
Get more information on Peregrine Pharmaceuticals and free access to the in-depth equity report at:
XOMA Corp. (NASDAQ: XOMA) shares dropped 27.75 percent to close at $6.82 a share Wednesday. The stock traded between $6.80 and $7.53 on volume 17.22 million shares traded. The company reported a net loss of $124.1 million, or $1.43 per share, for the full year 2013, up from a net loss of $71.1 million, or $1.10 per share, a year ago. Shares of XOMA are up approximately 35.0 percent year-to-date.
Get more information on XOMA free access to the in-depth equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Five Star Equities